EP4069191A1 - (s)-3-[1-methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication - Google Patents
(s)-3-[1-methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medicationInfo
- Publication number
- EP4069191A1 EP4069191A1 EP20820563.3A EP20820563A EP4069191A1 EP 4069191 A1 EP4069191 A1 EP 4069191A1 EP 20820563 A EP20820563 A EP 20820563A EP 4069191 A1 EP4069191 A1 EP 4069191A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methylpyrrolidin
- pyridine
- precursors
- derivatives
- analogues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 90
- 239000002243 precursor Substances 0.000 title claims abstract description 27
- 239000007787 solid Substances 0.000 title claims abstract description 12
- 229940126702 topical medication Drugs 0.000 title claims description 20
- 239000000126 substance Substances 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000004877 mucosa Anatomy 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 8
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 6
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 7
- 239000000084 colloidal system Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 31
- 210000000265 leukocyte Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 231100000263 cytotoxicity test Toxicity 0.000 description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 8
- 229960002715 nicotine Drugs 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 3
- 101710200814 Melanotropin alpha Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 2
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000208292 Solanaceae Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003515 anti-microbian Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 208000036622 Mesenteric occlusion Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 102000055276 human IL3 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Abstract
The invention relates to a (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical. According to the invention the substance is a colloid of fine solid and/or liquid particles in a fluid.
Description
(S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication
D e s c r i p t i o n
The present invention relates to a (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives - containing pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication. In addition the invention relates to a topical medication.
Field of invention
(S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, also known as nicotine, is an alkaloid found predominantly in plants like tobacco and cocoa and in lower quantities even in plants like tomato, potato, eggplant and green pepper, all belonging to the nightshade family of plants (Solanaceae). (S)-3-[1- Methylpyrrolidin-2-yl]pyridine is accumulated in the leaves of these plants while its biosynthesis is taken place in the particular roots. Thereby, (S)-3-[1-Methylpyrrolidin-2- yl]pyridine constitutes approximately 0,6 to 0,3% of the dry weight of for example the tobacco plant and is present in the range of 2 to 7 pg/KG of various edible plants.
Further, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine is a stimulant drug acting as an agonist to most nicotinic acetylcholine receptors (nAChR). In lesser doses of approximately 1 mg the substance adds on as a stimulant in mammals, while high amounts of approximately 50 to 100 mg can start being harmful.
(S)-3-[1-Methylpyrrolidin-2-yl]pyridine is hygroscopic, oily, colorless or pale yellow liquid, which is miscible with water and in its base form comprises a pyridine odor. (S)-3-[1- Methylpyrrolidin-2-yl]pyridine comprises a molecular weight of approximately 172 g/mol, is readily soluble in alcohol, ether or light petroleum. Further, (S)-3-[1-Methylpyrrolidin-2- yl]pyridine forms salts with acids that are solid and water soluble. The substance is further absorbed from the intact skin and by the mucosa. Thereby, (S)-3-[1-Methylpyrrolidin-2- yl]pyridine undergoes extensive first pass metabolism when administered to the skin. Furthermore, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine easily penetrates the skin, particularly the mucosa. The substance is able of being quickly distributed throughout the bloodstream and is even able to cross the blood-brain-barrier. The half-life of (S)-3-[1-Methylpyrrolidin-2- yl]pyridine in the body is approximately two hours.
(S)-3-[1-Methylpyrrolidin-2-yl]pyridine mentioned within the scope of the invention is always understood as (S)-3-[1-Methylpyrrolidin-2-yl]pyridine itself, analogues thereof, precursors thereof, its derivatives or nicotine which mimic the effect of (S)-3-[1-Methylpyrrolidin-2- yl]pyridine, either alone or in combination with other active substances can be used.
Background of the invention
In US 6479076 B2 a composition containing nicotine and an uncrosslinked, water-insoluble vinylpyrrolidone copolymer is applied on the skin of patients in the form of a gel, ointment, solution, suspension or film, which slowly releases nicotine and creates levels of the drug in the blood to reduce nicotine-craving in smokers, thereby assisting in smoking-cessation programs. The disadvantage of such a delivery system is that nicotine is used for smoking cessation therapy, wherein the use of nicotine is only administered when the craving for a cigarette is increased.
Detailed description of the invention
This problem is solved according to the invention by all features of claim 1. The depending claims specify embodiments. Further, this problem is also solved by all features of claim 10 wherein the dependent claims specify possible embodiments.
The special benefit of this invention is that a certain dosage of (S)-3-[1-Methylpyrrolidin-2- yl]pyridine, analogues thereof, precursors thereof or its derivatives, can be administered and reliably delivered to the desired destination within the body.
Advantageously, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives can be used as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication. Thereby the topical forms are presented as creams and/or gels and/or ointments and/or pastes. Thereby they can contain one or more active ingredients dissolved or uniformly dispersed in a base or suitable excipients like emulsifiers, viscosity-increasing agents, antimicrobial agents, antioxidants, or stabilizing agents. Further also antimicrobial agents can be an advantage. Another advantage is that the medication neither irritates nor sensitizes the skin. A smooth, inert, odourless, physically and chemically stable substance, compatible with the skin is preferred. Advantageously it comprises a consistency that spreads and softens easily. In order to be able to be applied to large open wounds or severely injured skin a sterile condition is preferred.
In one preferred embodiment of the invention (S)-3-[1-Methylpyrrolidin-2-yl]pyridine is intended as an ointment and/or lotion and/or cream and/or gel and/or tincture. Thereby ointments are homogeneous, semi-solid preparations intended for external application to the skin or mucous membranes. Further, they can be used as emollients or for the application of active ingredients to the skin for protective, therapeutic, or prophylactic purposes. Ointments are formulated using hydrophobic, hydrophilic, or water-emulsifying bases to provide preparations that are immiscible, miscible, or emulsifiable with skin secretions. Further ointments can be derived from hydrocarbon (fatty), absorption, water-removable, or water- soluble bases. Lotions are composed equally to ointments with the distinction that lotions are in general more liquid. Thereby lotions can be distributed more easily, especially on enlarged areas. Moreover, creams are homogeneous, semi-solid preparations consisting of opaque emulsion systems. Advantageously their consistency and rheological properties depend on the type of emulsion. Thereby, either water-in-oil or oil-in-water is preferred. Further, creams are intended for the application to the skin or certain mucous membranes in order to generate protective, therapeutic, or prophylactic purposes. Preferably, a cream is a soft, cosmetically acceptable type of preparation. Moreover, gels are usually homogeneous, clear, semi-solid preparations consisting of a liquid phase within a three-dimensional polymeric matrix with physical or sometimes chemical cross-linkage by means of suitable gelling agents. Preferably gels are applied to the skin or certain mucous membranes for protective, therapeutic, or prophylactic purposes. The same applies for tinctures, which are preferably administered with a device like a brush or rod in order to keep the target area sterile
In one possible embodiment of the invention (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof or its derivatives, is intended for application on the skin, particularly on the mucosa. The skin is an organ of the integumentary system of mammals consisting of multiple layers epithelial tissues with underlying muscles and organs. Thereby, the mucosa is a particular kind of skin, so called mucous membrane. The mucosa is mostly of endodermal origin and is involved in absorption and recreation. The mucosa of the present invention particularly refers to the oral and/or nasal cavity and/or the respiratory tract. For the skin the stratum corneum constitutes the skin barrier for the diffusion of substances. Herein, the application of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine as a substance applied to the skin is able to transdermal penetrate the stratum corneum. Preferably, the solution is thereby applied as a topical medication. Therefore, the particles are of an
adequate size for penetrating the skin. Said adequate size of particles regards to liquid and/or solid components within the topical medication. However, it is provided that the sizes are valid for the migration through the skin. A preferred size is thereby approximately 1pm to approximately 15pm in diameter. Preferably, the size is between approx. 5pm to approx. 10pm in diameter. The application of the substances to the skin allows an uptake into the bloodstream where the substance can affect the organism and thereby reduce the symptoms of diverse diseases. It is an advantage of an application to the skin that no digestion is required and the effective substance can be applied in the vicinity of the target tissue. The substance is directly transferred via the bloodstream to the predetermined pharmacological target location. Moreover, an application to the skin is fast drying, quickly absorbed and non irritating. Further, it is invisible after application and a reliable intake occurs. Further, applying a topical medication to the outer skin is an advantage for individuals needing a repeated administration of the substance since a topical medication can be applied locally without any effort of administering.
Furthermore, it can be provided that (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof or its derivatives, contain a preservative and a vehicle substance. The present delivery system contains a water-based and/or oil-based formulation. Thereby, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine is a formulation, which is soluble in or miscible with a liquid carrier. Another advantage is that the substance is soluble or miscible at room temperature. Alternatively and/or additionally, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine may be in form of a salt, which is solid at room temperature but can be dissolved in the liquid carrier, particularly in water and/or oil. Therefore, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine like its salt formulations are generally soluble in water and/or oil. A process of mixing can occur in order to generate a homogeneous liquid mixture. Beneath (S)-3-[1-Methylpyrrolidin-2-yl]pyridine also pharmacological analogues or derivatives or substances which mimic the effect of (S)-3- [1-Methylpyrrolidin-2-yl]pyridine, either alone or in combination with other active substances can be used. Preferably the substance contains liposomes and/or triglycerides and/or ceramides and/or lecithin and/or squalene and/or dimethyl sulfoxide in order to be compatible with an application to the skin, particularly the mucosa.
In one special embodiment of the invention (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof or its derivatives comprise a concentration of 0,3 mg/ml to 4,5
mg/ml, preferably 1,5 mg/ml to 3,0 mg/ml. The concentration of the active agent further depends on the liquidity at skin temperature (approximately 32°C) and/or the temperature of the body (approximately 36°C). Herein, the delivery system applies a dose of the active agent of about 0,3 mg/ml to 4,5 mg/ml per unit dose. Preferably, 1,5 mg/ml to 3,0 mg/ml is applied. Advantageously, the applied concentration of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine is not toxic. Using a cytotoxic compound can result in a variety of cell fates. The appearance of cytotoxic concentrations can result in necrosis (loss of membrane integrity) and thereby cell lysis, stopping cell growth and dividing or even apoptosis. In order to investigate the cytotoxicity level of certain substances cytotoxicity assays are widely used in the pharmaceutical industry. Further indicators being investigated in order to determine the level of cytotoxicity are for example TNFa (tumor necrosis factor alpha), IFNy (Interferon gamma) or IL-6 (interleukin). TNFa is a cell signaling protein mainly involved in systemic inflammation. Cells that produce TNFa are mainly macrophages, lymphocytes, mast cells, or neurons. However, the main function of TNFa is in the regulation of immune cells. Further, IFNy is a soluble cytokine. IFNy is a cytokine that is critical for immunity against viral, bacterial and protozoal infections. Thereby it is an important activator of macrophages and inducer of MHC (major histocompatibility complex) expression. IFNy has antiviral, immunoregulatory and anti-tumor properties. Further IL-6 is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. In mammalian IL-6 is secreted by T-cells and macrophages to stimulate an immune response.
Advantageously, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof or its derivatives, triggers stimulation of cholinergic receptors, particularly nicotinic receptors. Nicotine acetylcholine receptors (nAChR) are neuronal receptor proteins that signal upon a chemical stimulus. The cholinergic receptors are forming ligand gated ion channels in the plasma membrane of the certain neuron. They are expressed on the presynaptic and postsynaptic side of the neuro muscular junctions. As neurotropic receptors they are directly linked to ion channels and thereby are not dependent on second messengers. Neuron receptors are found in the central nervous system as well as in the peripheral nervous system of mammalians. Generally, ligand gated ion channels require the binding of a chemical messenger for opening. The endogenous agonist is acetylcholine wherein they are also triggered by (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof or its derivatives. The action that (S)-3-[1-Methylpyrrolidin-2-yl]pyridine
binds to nicotine cholinergic receptors can be regarded as a key energy source of the cell, as this is responsible for upregulating of energy. All nicotine cholinergic receptors produce excitatory postsynaptic effects. Thereby, energy is upregulated previous to an excitatory postsynaptic effect. Further, the administration of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine upregulates the release of endogenous alpha-MSH. The melanocytes stimulating hormone (MSH) belong to peptide hormones that are produced in the central nervous system. These hormones stimulate the production inducing melanin by melanocytes in the skin and in the hair. Alpha-MSH induces multiple responses in nearly all cells of mammalians, thereby significantly improving and also maintaining good health conditions. Alpha-MSH is further related to chemical energy levels within the mammalian body and thereby fundamental for an optimal body performance.
In one advantageous embodiment of the invention is (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof or its derivatives is used for the treatment of diseases related to pain. Further, these substances also modulate many disease pathologies like skin physiology, melanocytes function, nerve regeneration, behavior and learning as well as memory, obesity and energy metabolism, brain inflammation, autoimmune diseases, septic shock, endotoxemia, renal ischemic occlusion and reperfusion, mesenteric occlusion and reperfusion, diabetes, viral related diseases like H1N1 intoxications, viral related intoxications like Ebola, congenital mal formations and cancer as well as inflammatory diseases. Particularly, the substance is related to diseases as joint pain and further to diseases related to nerves as well as to skin. Mainly, these diseases can be treated in mammalians preferably in humans and/or animals.
Advantageously, (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof or its derivatives, are administered every 24 hours. Preferably, the substance is administered every 12 hours, preferably every 6 hours. Thereby, the frequency of administration depends upon the variety of disease. In administration every 2 to 3 hours is likewise possible. Preferably the frequency of application depends on the severity of the disease. An application every two or three hours can be an advantage.
The present invention further relates to a topical medication with a substrate which is applied on the skin of a human and/or animal body, wherein the substrate comprises (S)-3-[1-
Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives. The topical medication is appropriate for transdermal delivery of an active substance, preferably (S)-3-[1-Methylpyrrolidin-2-yl]pyridine to an area of skin. Moreover, the topical medication administeres the pharmacological relevant substance, particularly (S)-3-[1-Methylpyrrolidin- 2-yl]pyridine in single dosages. Typically the application occurs over a certain area, particularly of skin and/or mucosa of at least 5 m2, preferably no more than about 100 m2. Preferably, the dose will be applied of an area of skin of approximately 20 cm2, depending on the area which is suffering from a disease. With the manufacture of the topical medication preferably a homogeneous mixture is obtained. During storage the topical medication should be protected from light, moisture, and damage due to handling and transportation. Preferably the topical medication is stored in flexible tubes of suitable metal or plastic. As an advantage preparations for nasal, aural, vaginal, or rectal use are supplied in containers adapted for appropriate delivery of the product to the site of application or are supplied with a suitable applicator.
The present invention is further described in detail with respect to the accompanying examples and figures. Features discussed with the description of the examples and the figures can be freely combined with each other. The features mentioned in the claims and specifications are essential to the invention, either in themselves or in given combination.
Examples and Figures
In a first example a treatment with (S)-3-[1-Methylpyrrolidin-2-yl]pyridine of viral diseases like for example H1N1 was tested on chicken, infected with the H1N1 virus. Therefore, 30000 diseased chicken were divided into two groups of 15000. One group was treated with (S)-3- [1-Methylpyrrolidin-2-yl]pyridine at doses of 0,002 mg/kg each 24 hours. The other group represented the control group. 24 hours after treatment the treated group began to lay off eggs in contrary to the control group, which turned down the production of eggs. The treatment against intoxication was tested related to mercury, CN, cadmium, arsenic, herbicides, pesticides. As an example mercury poisoning induces a generalized failure, typical to low levels of energy, so that the mortality level is high. As a result 6 in 8 rats died at the dose of 4,5 mg/kg of mercury (HgHCI). In any of the organs edema and hemorrhage was
examined. After a treatment of 0,0937 mg/ml with (S)-3-[1-Methylpyrrolidin-2-yl]pyridine mortality was reduced to 0,625 of 8 rats.
Fig. 1 a diagram showing a treatment of a group of humans (n = 10/each) ulcer with
(S)-3-[1-Methylpyrrolidin-2-yl]pyridine
Fig. 2a a diagram showing a cytotoxicity test with WI-38 cells treated with (S)-3-[1- Methylpyrrolidin-2-yl]pyridine
Fig. 2b a diagram showing a cytotoxicity test with A549 cells treated with (S)-3-[1- Methylpyrrolidin-2-yl]pyridine
Fig. 2c a diagram showing a cytotoxicity test with HS683 cells treated with (S)-3-[1-
Methylpyrrolidin-2-yl]pyridine
Fig. 3 a diagram showing a cytotoxicity test of human PBLs treated with (S)-3-[1-
Methylpyrrolidin-2-yl]pyridine
Fig. 4a a diagram showing the influence of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on the proliferation of WI-38 cells
Fig. 4b a diagram showing the influence of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on the proliferation of A549 cells
Fig. 4c a diagram showing the influence of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on the proliferation of HS683 cells
Fig. 5a a diagram showing the effect of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on
TNF-a production
Fig. 5b a diagram showing the effect of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on
IFN-g production
In a further example (Fig. 1) the effect of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine is shown. Thereby the healing process of an ulcer is examined as a basic condition. Different ulcers (n = 10 for each group) are examined each after 72 h treatment with (S)-3-[1-Methylpyrrolidin-2- yl]pyridine (Group A), treatment with antimicrobians/antimycotics (group B) and without treatment (group C). As a result the treatment with (S)-3-[1-Methylpyrrolidin-2-yl]pyridine resulted in an increased healing effect (group A) compared to the treatment with antimicrobians/antimycotics (group B) and without treatment (group C) (Fig. 1).
In a further example cytotoxicity tests were performed with three different cell lines (Fig. 2a, 2b, 2c):
- WI-38 (human diploid cell line from normal embryonic lung tissue)
- A549 (human lung adenocarcinoma epithelial cell line) and
- HS683 (human neuronal glioma cell line).
Thereby, cell viability was determined on the basis of the mitochondria-dependent reduction of MTT (3-[4,5-dimethyltiazol 2yl]-2,5-diphenyltetrazolium bromide) to formazan. Cell lines (2x105cell/ml) as well as leukocytes (2x106 cells/ml) were cultured in 96-well plates for 48 hours in the presence of various concentrations of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine (5- 0,05 mg/ml). Next cells were treated with 20 pi of MTT. After 3 hours of incubation at 37°C, the formazan blue formed in the cells was dissolved in 100 mI of SDS (sodium dodecylsulfate) for 3 hours in 37°C. The optical density was measured at 570 nm.
After the cytotoxicity tests LC50 (LCso-lethal concentration, 50%-dose required to kill half of the cells after a specified test duration) were estimated for each cell lines and PBLs (leukocytes of peripheral blood). Additionally for PBLs LCio and LCs were calculated. On the basis of the results for leukocytes three different concentrations of (S)-3-[1-Methylpyrrolidin- 2-yl]pyridine were selected for evaluation of the effect of cytokine production.
Further, a proliferation test was prepared for the same three cell lines: WI-38, A549 and HS 683. 3x104 WI-38 cells and 2x104 A549 and HS 683. Cells were seeded into each wells in 96-well culture plates in appropriate culture medium with 10% FBS (fetal bovine serum). After 24 h incubation in 37°C/5%C02 medium were removed and replaced with tested
concentrations of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine in culture medium. After 96 hours incubation in 37°C/5%CC>2 MTT assay was performed for establishing the cell viability.
Studies of the effect of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on cytokine production was performed on PBLs isolated ex vivo from 10 healthy volunteers (male 5; female 5; age 23- 45). Next, leukocytes were treated with selected, nontoxic concentrations of (S)-3-[1- Methylpyrrolidin-2-yl]pyridine (1 mg/ml; 500 pg/ml, 300 pg/ml) without or with 5 pg/ml of LPS (lipopolysaccharide). After 24 hours of incubation in 37°C/5%CC>2 samples of leukocytes and supernatants were collected. For evaluation of the influence of (S)-3-[1-Methylpyrrolidin-2- yl]pyridine on IFN-y (interferon) production additionally samples were collected after 72 hours of incubation.
Cytokine levels were determined using ELISA kits (BD Biosciences, USA) for human IFNy, TNF-a and IL-6 and DuoSet for human IL-3 (R&D Systems, USA) according to the producers’ instructions. The optical density was measured at 450 nm using a Multiskan RC spectrophotometric reader (Thermo Labsystems, USA), Cytokine concentrations were expressed in pg/ml.
In summary the LC50 of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine for a cell line WI-38 is 3,0 mg/ml, for the cell line A549 is 4,5 mg/ml and for the cell line HS-683 is 3,5 mg/ml.
In Figure 3 the results of the cytotoxicity test of human PBLs is shown.
On the basis of the results of MTT assay for human leukocytes the LC50, LC10 and LC5 were evaluated. The LC50 is a concentration of 7 mg/ml (S)-3-[1-Methylpyrrolidin-2-yl]pyridine. The LC10 is in a concentration of 1 mg/ml and LC5 is in a concentration of 0,5 mg/ml (S)-3-[1- Methylpyrrolidin-2-yl]pyridine.
In a further example (Figures 4a to 4c) the influence of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on the proliferation of divers cell lines was investigated. Figure 3a shows the effect on WI-38 cells. For the cell line WI-38 1,0 mg/ml of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine inhibits 50% of the proliferation of these cells, whereby 4,5 mg/ml inhibits a proliferation of 99%.
For the cell line A549 a concentration of 2,0 mg/ml (S)-3-[1-Methylpyrrolidin-2-yl]pyridine inhibits 50% of the proliferation whereas the concentration of 5,5 mg/ml inhibits 99% of the proliferation.
For the cell line HS-683 2,9 mg/ml (S)-3-[1-Methylpyrrolidin-2-yl]pyridine inhibits 50% of the proliferation of these cells wherein 99% of proliferation are inhibited in a concentration of 5,5 mg/ml.
In another example the cytokine production is evaluated utilizing the effect of (S)-3-[1- Methylpyrrolidin-2-yl]pyridine on TNF-a production. As shown in Figure 4a the preparation increases the level of cytokines in a dose-dependent manner. The effect was observed only for unstimulated human PBLs.
At the same time studies of the effect of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine on IFN-y production showed that the preparation strongly decreases the level of interferon in a dose- dependent manner. The effect was observed for LPS stimulated human PBLs. There were poor or no spontaneous IFN-g production after 24 hours and 72 hours of incubation of PBLs. At the same time no effect of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine was observed for IL-6 production by human PBLs.
Shown in Figures 1 to 5 allow cytotoxicity of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine was observed. The preparation inhibits 50% of cell proliferation in doses higher than 1 mg/ml. All other concentrations were harmless. Preparation increased TNF-a production by unstimulated human PBLs in a dose-dependent manner. Further, (S)-3-[1-Methylpyrrolidin-2- yl]pyridine strongly reduces IFN-g production by LPS-stimulated human PBLs. The effect was again dose-dependent.
Aforesaid discussion of the different embodiments is only carried out by the way of example and does not limit the scope of the protection of the present invention.
Claims
1. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication.
2. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to Claim 1 , characterized in that the substance is one of the following: ointment, lotion, cream, gel, tincture.
3. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to Claim 1 or 2, characterized in that the substance is intended for application on the skin, particularly on the mucosa.
4. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to Claim 3, characterized in that particles of the substance are for penetrating the skin, wherein a preferred size is approximately 1pm to approximately 15pm in diameter, preferably between approximately 5pm to approximately 10pm in diameter.
5. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to one of Claims 1 to 4, characterized in that the substance contains a preservative and a vehicle substance.
6. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to Claim 5, characterized in that the substance contains liposomes and/or triglycerides and/or ceramides and/or lecithin and/or squalene and/or dimethyl sulfoxide.
7. S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to one of Claims 1 to 6, characterized in that the concentration of (S)-3-[1-Methylpyrrolidin-2-yl]pyridine is 0,3 mg/ml to 4,5 mg/ml, preferably 1,5 mg/ml to 3,0 mg/ml.
8. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to one of Claims 1 to 7, characterized in that a stimulation of cholinergic receptors, particularly nicotinic, occurs.
9. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to one of Claims 1 to 8, for the treatment of diseases related to pain, particularly joint pain and/or nerves and/or skin, in humans and/or in animals, particularly in mammalians.
10. (S)-3-[1-Methylpyrrolidin-2-yl]pyridine analogues thereof, precursors thereof, or its derivatives, according to one of Claims 1 to 9, characterized in that the treatment is intended to administer every 24 hours, preferably every 12 hours, particularly preferably every 6 hours.
11. Topical medication with a substrate which is applied on the skin of a human and/or animal body, characterized in that the substrate comprises (S)-3-[1-Methylpyrrolidin- 2-yl]pyridine analogues thereof, precursors thereof, or its derivatives according to one of claims 1 to 10.
12. Topical medication according to Claim 11, characterized in that the substance is dispensed in a single dosage and/or in a multi dosage.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU101520A LU101520B1 (en) | 2019-12-02 | 2019-12-02 | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication |
| PCT/IB2020/061400 WO2021111339A1 (en) | 2019-12-02 | 2020-12-02 | (s)-3-[1-methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4069191A1 true EP4069191A1 (en) | 2022-10-12 |
Family
ID=69375895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20820563.3A Pending EP4069191A1 (en) | 2019-12-02 | 2020-12-02 | (s)-3-[1-methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4069191A1 (en) |
| LU (1) | LU101520B1 (en) |
| WO (1) | WO2021111339A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703458D0 (en) * | 1997-09-25 | 1997-09-25 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
| US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
| CN101437515B (en) * | 2006-05-08 | 2016-04-20 | 阿图罗·索利斯埃雷拉 | Nicotine, its analog, its precursor or derivatives thereof are used for the application by improving the various pathological process for the treatment of with the α-MSH preventing form or form of therapy to participate in |
-
2019
- 2019-12-02 LU LU101520A patent/LU101520B1/en active IP Right Grant
-
2020
- 2020-12-02 WO PCT/IB2020/061400 patent/WO2021111339A1/en unknown
- 2020-12-02 EP EP20820563.3A patent/EP4069191A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021111339A1 (en) | 2021-06-10 |
| LU101520B1 (en) | 2021-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tanaji | Emulgel: A comprehensive review for topical delivery of hydrophobic drugs | |
| EP0641561B1 (en) | Medical device for the administration of active ingredients or drugs at very low doses, particularly homeopathic drugs | |
| JP6434104B2 (en) | Diclofenac formulation | |
| US7033998B2 (en) | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof | |
| SK64599A3 (en) | Substantially homogenous liquid composition capable for percutaneous delivery of active agents and percutaneous delivery system | |
| US20120024743A1 (en) | Transdermal pharmaceutical preparations | |
| JPS60152413A (en) | Composition for local application with improved percutaneousdrug release by menthol | |
| US7291591B2 (en) | Alcohol-free transdermal insulin composition | |
| US20180318398A1 (en) | Methods and compositions using ampk activators for pharmacological prevention of chronic pain | |
| LU101520B1 (en) | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication | |
| EP3675814A1 (en) | Composition for topical treatment of non-microorganism-caused inflammatory skin and mucous-membrane diseases | |
| US20040202640A1 (en) | Method for topical treatment of scars with rotein Kinase C inhibitors | |
| LU101510B1 (en) | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of an aerosol and dispensing device | |
| JPH11509515A (en) | New pharmaceutical prescription | |
| KR100192149B1 (en) | Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline | |
| Surekha et al. | Emulgel-An Overview | |
| US9233085B1 (en) | Topical application of AMPK activators for pharmacological prevention of chronic pain | |
| Aher et al. | Mucoadhesive Formulations for Buccal Mucosa | |
| CA3101291A1 (en) | (s)-3-(1-methylpyrrolidin-2-yl)pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a parenteral administration and a process for the preparation of an injectable substance | |
| EP4069192A1 (en) | (s)-3-[1-methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet | |
| CZ22799A3 (en) | Preparation for treating and/or prevention of dementia | |
| Thejaswini et al. | Critical Parameters Characterization of Gel Dosage Form of" Novel Neutraceutical Drug Combination" | |
| Likitha et al. | Emulgel: A Novel Topical Drug Delivery | |
| Mary Sheela et al. | Formulation and evaluation of gel using ink gland extract from Indian squid Loligo duvauceli | |
| ABRAHAM et al. | Evaluation and Permeation Studies of Transdermal Patches of Ketorolac Tromethamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220704 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20240322 |